Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden.

Description

A sample of 507 patients with coronary disease participated in a study designed to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. The patients were randomized to rosuvastatin 40 mg/day or placebo for 24 months (ASTEROID study). After the intervention period, several lipoprotein-lipid profile indices were improved, such as LDL [-53.3% (95% CI, -56.0 to -50.6%)] and HDL cholesterol [+13.8% (95% CI, 11.0-16.6)]. Quantitative coronary angiography analyses showed that the two measures of stenosis (i.e., percent diameter stenosis and minimum lumen diameter) improved significantly (-1.3±8.0% for percent diameter stenosis and +0.03±0.20% for mean lumen diameter) in response to rosuvastatin therapy. These results are in line with other results reported by this trial with respect to atherosclerosis burden assessed by intravascular ultrasound.